Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
| Autor: | Maria Gomez-Caraballo, Aaron N. Hata, Justin F. Gainor, Eugene J. Mark, Yasushi Goto, Jeffrey A. Engelman, Alona Muzikansky, Michael Lanuti, Emine Bozkurtlar, Tiffany Huynh, Mari Mino-Kenudson, Hironori Uruga |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male 0301 basic medicine Pulmonary and Respiratory Medicine Programmed cell death Pathology medicine.medical_specialty Lung Neoplasms Apoptosis Adenocarcinoma CD8-Positive T-Lymphocytes B7-H1 Antigen 03 medical and health sciences Lymphocytes Tumor-Infiltrating 0302 clinical medicine PD-L1 Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Adjuvant therapy Humans Medicine Lymph node Aged Neoplasm Staging Aged 80 and over Lung biology business.industry Tumor-infiltrating lymphocytes Middle Aged Prognosis medicine.disease Primary tumor Survival Rate 030104 developmental biology medicine.anatomical_structure Oncology Lymphatic Metastasis 030220 oncology & carcinogenesis biology.protein Cancer research Immunohistochemistry Female Neoplasm Recurrence Local business Follow-Up Studies |
| Zdroj: | Journal of Thoracic Oncology. 12:458-466 |
| ISSN: | 1556-0864 |
| Popis: | Programmed death ligand 1 (PD-L1) expression determined by immunohistochemistry (IHC) may serve as a predictive biomarker for anti-PD-1/PD-L1 therapies; however, little is known about intertumoral heterogeneity of PD-L1 expression determined by IHC in lung adenocarcinomas (ADCs), and there have been conflicting results on the prognostic role of PD-L1 expression in ADCs.PD-L1 expression was evaluated in resected stage II and III ADCs by using various cutoffs and correlated with clinicopathologic parameters and survival. PD-L1 expression was also compared between the primary tumor and lymph node metastases.There were 109 study cases. PD-L1 expression was seen in 56 (51%), 43 (39%), and 19 (17%) when cutoffs of at least 1%, at least 5%, and at least 50%, respectively, were used. Abundant intratumoral CD8-positive T cells were a significant predictor of the expression in the primary tumor, with cutoffs of 1% and 5% (p0.001 for both) by multivariate analysis, whereas they were a nonsignificant predictor of the expression with a 50% cutoff (p = 0.076). PD-L1 expression was concordant between the primary tumor and nodal metastasis in most of the cases, but it was discrepant in up to 38%. The discrepancy was attributed in part to different predominant histologic patterns between the primary and metastatic tumors. In the entire cohort, PD-L1 expression with all cutoffs had no bearing on 5-year recurrence-free survival.PD-L1 expression is associated with abundant intratumoral CD8-positive T cells in resected ADCs, suggesting a predictive role of PD-L1 expression in anti-PD-1/PD-L1 therapies; however, the possible intertumoral heterogeneity of PD-L1 expression raises a concern about selecting the most appropriate sample for PD-L1 IHC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|